- Dimerix buys a kidney injury drug; Arpeggio appears to be winding downPlus, news about Takeda, Novartis and Regenxbio. 🤝 Mission sells kidney injury drug to Dimerix: Dimerix will pay $5 million upfront for Mission’s Phase 2-ready candidate for acute kidney injury,…Endpoints · 10d ago↗ source
- STAT+: The end for GSK’s chronic cough treatmentSonothera's ultrasound gene therapy delivery, a new Alzheimer's drug controversy, and more biotech news from The ReadoutSTAT · 10d ago↗ source
- Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances<figure><div><img src="https://imgproxy.divecdn.com/idsdMAHsPbXObDUtQW2qRG7uveBUVv6HCTn9NTtlDOI/g:nowe:0:0/c:1207:682/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0x…